Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

by Bersanelli, Melissa
Published in Immunotherapy (2020)

COVID-19 and the newly rediscovered multidisciplinarity

by Bersanelli, Melissa
Published in Immunotherapy (2020)

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

by Bersanelli, Melissa, Buti, Sebastiano
Published in World J Clin Oncol (2017)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

by Bersanelli, Melissa, Buti, Sebastiano
Published in Ther Adv Med Oncol (2017)

Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?

by Bersanelli, Melissa, Petrelli, Fausto
Published in J Thorac Dis (2018)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

by Bersanelli, Melissa, Leonardi, Francesco, Buti, Sebastiano
Published in Cancer Manag Res (2018)

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a “transcriptomic compass”?

by Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
Published in Ann Transl Med (2019)

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”...

by Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
Published in Hum Vaccin Immunother (2021)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

by Buti, Sebastiano, Leonetti, Alessandro, Dallatomasina, Alice, Bersanelli, Melissa
Published in Core Evid (2016)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

by Leonetti, Alessandro, Leonardi, Francesco, Bersanelli, Melissa, Buti, Sebastiano
Published in Ther Clin Risk Manag (2017)

Family history of cancer and DNA damage response genes: Two sides of the same coin?

by Cortellini, Alessio, Bersanelli, Melissa, Ficorella, Corrado, Buti, Sebastiano
Published in Thorac Cancer (2018)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

by Parisi, Alessandro, Cortellini, Alessio, Cannita, Katia, Bersanelli, Melissa, Ficorella, Corrado
Published in Case Rep Oncol Med (2019)

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

by Bersanelli, Melissa, Buti, Sebastiano, Santoni, Matteo, Ziglioli, Francesco, Maestroni, Umberto
Published in Ann Transl Med (2019)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

by Bersanelli, Melissa, Brunelli, Matteo, Gnetti, Letizia, Maestroni, Umberto, Buti, Sebastiano
Published in Ther Adv Med Oncol (2020)

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the “embarrassment of riches”

by Buti, Sebastiano, Leonetti, Alessandro, Lattanzi, Elisabetta, D’Abbiero, Nunziata, Bersanelli, Melissa
Published in Ann Transl Med (2019)

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer

by Cattrini, Carlo, Bersanelli, Melissa, Latocca, Maria Maddalena, Conte, Benedetta, Vallome, Giacomo, Boccardo, Francesco
Published in Cancers (Basel) (2020)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

by Bersanelli, Melissa, Buti, Sebastiano, Camisa, Roberta, Brighenti, Matteo, Lazzarelli, Silvia, Mazza, Giancarlo, Passalacqua, Rodolfo
Published in Cancers (Basel) (2014)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

by Banna, Giuseppe Luigi, Cantale, Ornella, Bersanelli, Melissa, Del Re, Marzia, Friedlaender, Alex, Cortellini, Alessio, Addeo, Alfredo
Published in Oncol Rev (2020)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

by Roviello, Giandomenico, Buti, Sebastiano, Cattrini, Carlo, Mennitto, Alessia, Messina, Carlo, Airoldi, Chiara, Vannini, Gianmarco, Bersanelli, Melissa
Published in Ther Adv Urol (2021)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

by Bersanelli, Melissa, Giannarelli, Diana, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello, Nouvenne, Antonio, Ticinesi, Andrea, Meschi, Tiziana, Procopio, Giuseppe, Danielli, Riccardo
Published in Future Oncol (2021)